SCHEMBL6429151

SCHEMBL6429151

O=C(CC1SC(NC2CC3C=CC2C3)=NC1=O)Nc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 7/20 0.41
ALDH1A1 P00352 6/20 0.41
MAPT P10636 4/20 0.41
HPGD P15428 2/20 0.41
GAA P10253 2/20 0.41
MAP2K1 Q02750 1/20 0.41
ADAM17 P78536 1/20 0.41
MEN1 O00255 5/20 0.41
KDM4E B2RXH2 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
NSD2 O96028 1/20 0.39
POLB P06746 2/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6508258 0.91 MAP2K1 (0.43) CYP2C19KMT2AALDH1A1MAPTHPGD
SCHEMBL1606025 0.90 MAPT (0.46) KMT2AALDH1A1MAPTGAAMAP2K1
SCHEMBL6427276 0.90 CYP2C19 (0.56) CYP2C19KMT2AALDH1A1MAPTGAA
SCHEMBL1605665 0.86 ALDH1A1 (0.39) CYP2C19KMT2AALDH1A1MAPTHPGD
SCHEMBL6427842 0.86 ALDH1A1 (0.56) CYP2C19KMT2AALDH1A1HPGDGAA
SCHEMBL6427444 0.85 CYP2C19 (0.41) CYP2C19KMT2AALDH1A1MAPTGAA
SCHEMBL6427367 0.85 MAPT (0.37) ALDH1A1MAPTGAAKDM4ETDP1
SCHEMBL6426304 0.84 EPHX2 (0.34) KMT2AALDH1A1GAAMEN1TDP1
SCHEMBL6426662 0.82 EPHX2 (0.36) KMT2AALDH1A1MAPTGAAMEN1
SCHEMBL6427691 0.82 ALDH1A1 (0.33) KMT2AALDH1A1HPGDGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 CYP2C19 89/4885KMT2A 3213/4885ALDH1A1 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.